CD56-Positive Large B-cell Lymphoma

Abstract

CD56 (NCAM), a neural adhesion molecule, is normally expressed on natural killer cells and subsets of T cells and is commonly seen on hematolymphoid neoplasms such as plasma cell myeloma and acute myelogenous leukemia. It is uncommon in B-cell lymphoma. From 2001 to 2003 a cohort of 20 cases of CD56 B-cell lymphomas was identified by flow cytometry (<0.5% of all B-cell lymphomas studied) during a 2-year period. Most (90%) expressed CD10 and 5/5 tested cases were BCL6, suggesting a follicular origin. An extranodal disease presentation was seen in 45% and may be related to CD56 expression. These CD56 B-cell lymphomas may represent a new subset of large B-cell lymphoma. The relationship of cells with this antigenic profile to normal B-cell differentiation is explored.

CD56+ B-cell Neurolymphomatosis in a Cat

“…In man, CD56 positivity is a rare event in B-cell lymphoma and is usually recognized in neoplastic B cells derived from extranodal sites (Weisberger et al, 2006). Aberrant expression of CD56 by the neoplastic lymphoid cells is considered as a possible factor in infiltration of neoplastic cells into peripheral nerves (Misdraji et al, 2000;Weisberger et al, 2006). Here, we report the clinical, imaging and pathological findings of a primary, neurotropic, CD56 + B-cell lymphoma (neurolymphomatosis) in a cat.…”

“…Amongst these, neurolymphomatosis is defined as an infiltration of peripheral nerves or nerve roots by a neurotropic B-or T-cell lymphoma or with concur-rent leukaemia (Higgins et al, 2016). Neural cell adhesion molecule (also called CD56) is a key molecule responsible for mediating cell-to-cell adhesion and is typically expressed by neurons, glia, natural killer (NK) cells or T cells (Weisberger et al, 2006). In man, CD56 positivity is a rare event in B-cell lymphoma and is usually recognized in neoplastic B cells derived from extranodal sites (Weisberger et al, 2006).…”

“…Neural cell adhesion molecule (also called CD56) is a key molecule responsible for mediating cell-to-cell adhesion and is typically expressed by neurons, glia, natural killer (NK) cells or T cells (Weisberger et al, 2006). In man, CD56 positivity is a rare event in B-cell lymphoma and is usually recognized in neoplastic B cells derived from extranodal sites (Weisberger et al, 2006). Aberrant expression of CD56 by the neoplastic lymphoid cells is considered as a possible factor in infiltration of neoplastic cells into peripheral nerves (Misdraji et al, 2000;Weisberger et al, 2006).…”

“…Unfortunately, the expression of CD56 with respect to neoplastic B-cell ontogeny has not been fully investigated. In previous studies, human B-cell lymphomas with CD56 positivity were reportedly associated with a propensity for extranodal involvement and assumed to preferentially arise from the germinal centre stage, where B cells undergo neoplastic transformation with aberrant expression of CD56 (Weisberger et al, 2006;Isobe et al, 2007). To date, CD56 has not been detected in human primary B-cell neurolymphomatosis and further insight into the pathogenesis of primary B-cell neurolymphomatosis is required (Baehring et al, 2003).…”

“…To date, CD56 has not been detected in human primary B-cell neurolymphomatosis and further insight into the pathogenesis of primary B-cell neurolymphomatosis is required (Baehring et al, 2003). With respect to the biological importance of CD56, the previous studies of T-or NK-cell lymphomas and acute myeloid leukaemia with expression of CD56 indicate a highly aggressive clinical course and poor prognosis (Weisberger et al, 2006). In veterinary medicine, the diagnostic and prognostic significances of CD56 expression in B-cell neurolymphomatosis or in other neoplasms needs documentation in more cases in the future.…”